Literature DB >> 12924103

[Methotrexate therapy in rheumatologic diseases--an update].

Edmund Cauza1, Attila Dunky.   

Abstract

This article summarizes the recent literature on low-dose methotrexate in the rheumatologic illnesses. It reviews the efficacy of these agents, the use of combination therapy, and the importance of early treatment with this disease modifying antirheumatic drug. The anti-inflammatory and immunosuppressive effects as well as the toxicity of the drug in rheumatoid arthritis and other diseases are further defined.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12924103     DOI： 10.1046/j.1563-258x.2003.03034.x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  53 in total

1.  Methotrexate induced early onset pancytopenia in rheumatoid arthritis: drug allergy? Idiosyncrasy?

Authors:  Y Tanaka; K Shiozawa; Y Nishibayashi; S Imura
Journal:  J Rheumatol       Date:  1992-08       Impact factor: 4.666

Review 2.  Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine.

Authors:  R Blanco; V M Martínez-Taboada; M A González-Gay; J Armona; J L Fernández-Sueiro; M C González-Vela; V Rodríguez-Valverde
Journal:  Arthritis Rheum       Date:  1996-06

3.  Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group.

Authors:  C M Stein; T Pincus; D Yocum; P Tugwell; G Wells; O Gluck; G Kraag; H Torley; J Tesser; R McKendry; R H Brooks
Journal:  Arthritis Rheum       Date:  1997-10

4.  Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.

Authors:  R Rau; B Schleusser; G Herborn; T Karger
Journal:  J Rheumatol       Date:  1998-08       Impact factor: 4.666

5.  Methotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected cases.

Authors:  W S Wilke; P L Krall; R J Scheetz; T Babiak; T Danao; D J Mazanec; A M Segal; J D Clough
Journal:  Clin Exp Rheumatol       Date:  1991 Nov-Dec       Impact factor: 4.473

6.  Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial.

Authors:  H J Williams; J R Ward; J C Reading; R H Brooks; D O Clegg; J L Skosey; M H Weisman; R F Willkens; J Z Singer; G S Alarcón
Journal:  Arthritis Rheum       Date:  1992-03

7.  Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis.

Authors:  L D Graham; B L Myones; R F Rivas-Chacon; L M Pachman
Journal:  J Pediatr       Date:  1992-03       Impact factor: 4.406

8.  Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.

Authors:  J R O'Dell; C E Haire; N Erikson; W Drymalski; W Palmer; P J Eckhoff; V Garwood; P Maloley; L W Klassen; S Wees; H Klein; G F Moore
Journal:  N Engl J Med       Date:  1996-05-16       Impact factor: 91.245

9.  Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group.

Authors:  P Tugwell; T Pincus; D Yocum; M Stein; O Gluck; G Kraag; R McKendry; J Tesser; P Baker; G Wells
Journal:  N Engl J Med       Date:  1995-07-20       Impact factor: 91.245

10.  Methotrexate in severe ankylosing spondylitis: an open study.

Authors:  M C Creemers; M J Franssen; L B van de Putte; F W Gribnau; P L van Riel
Journal:  J Rheumatol       Date:  1995-06       Impact factor: 4.666
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.